Eli Lilly 2008 Annual Report Download - page 113
Download and view the complete annual report
Please find page 113 of the 2008 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103 -
104 -
105 -
106 -
107 -
108 -
109 -
110 -
111 -
112 -
113 -
114 -
115 -
116 -
117 -
118 -
119 -
120 -
121 -
122 -
123 -
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
 |
 |
PROXY STATEMENT
111111
Ownership of Company Stock
Common Stock Ownership by Directors and Executive Offi cers
The following table sets forth the number of shares of company common stock benefi cially owned by the directors,
the named executive offi cers, and all directors and executive offi cers as a group, as of February 3, 2009.
The table shows shares held by named executives in the Lilly Employee 401(k) Plan, shares credited to the
accounts of outside directors in the Lilly Directors’ Deferral Plan, and total shares benefi cially owned by each
individual, including the shares in the respective plans. In addition, the table shows shares that may be purchased
pursuant to stock options that are exercisable within 60 days of February 3, 2009.
Name 401(k) Plan Shares
Directors’ Deferral
Plan Shares 1
Total Shares Owned
Benefi cially 2
Stock Options Exercis-
able Within 60 Days of
February 3, 2009
Robert A. Armitage 1,932 — 63,424 335,371
Sir Winfried Bischoff — 16,237 18,237 11,200
Bryce D. Carmine 4,717 — 44,348 361,855
J. Michael Cook — 15,683 17,483 —
Michael L. Eskew — 4,513 4,513 —
Martin S. Feldstein, Ph.D. — 14,529 15,529 8,400
J. Erik Fyrwald — 16,673 16,786 —
Alfred G. Gilman, M.D., Ph.D. — 22,424 22,424 14,000
Karen N. Horn, Ph.D. — 35,769 35,769 14,000
John C. Lechleiter, Ph.D. 14,163 — 229,400 3 958,775
Ellen R. Marram — 14,529 15,529 5,600
Douglas R. Oberhelman — 0 0 —
Steven M. Paul, M.D. 552 — 43,538 568,396
Franklyn G. Prendergast, M.D., Ph.D. — 28,317 28,317 14,000
Derica W. Rice 5,559 — 59,689 123,385
Kathi P. Seifert — 24,176 27,709 14,000
Sidney Taurel 18,061 — 1,064,059 4 2,447,488
All directors and executive offi cers as a group (22 people): 1,925,653
1 See description of the Lilly Directors’ Deferral Plan, page 83.
2 Unless otherwise indicated in a footnote, each person listed in the table possesses sole voting and sole invest-
ment power with respect to the shares shown in the table to be owned by that person. No person listed in the
table owns more than 0.09 percent of the outstanding common stock of the company. All directors and executive
offi cers as a group own 0.17 percent of the outstanding common stock of the company. 1,800 of Mr. Cook’s shares
were on deposit in a margin account as of February 3, 2009.
3 The shares shown for Dr. Lechleiter include 13,470 shares that are owned by a family foundation for which he is a
director. Dr. Lechleiter has shared voting power and shared investment power over the shares held by the founda-
tion.
4 The shares shown for Mr. Taurel are presented as of his retirement, December 31, 2008, and include 17,304 shares
that are owned by a family foundation for which he is a director. Mr. Taurel has shared voting power and shared
investment power over the shares held by the foundation.